DAPT plus anticoagulant therapy: The difficult coexistence post-ACS in older patients with atrial fibrillation

Submitted: April 26, 2018
Accepted: May 30, 2018
Published: June 7, 2018
Abstract Views: 1066
PDF: 677
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Atrial fibrillation (AF) and coronary artery disease requiring percutaneous coronary intervention (PCI) and stenting often coexist in older patients. This poses the difficult problem of concurrent anticoagulant and double antiplatelet therapy (triple therapy). Current treatment guidelines do recommend triple therapy, especially in the course of acute coronary syndrome (ACS), with limitations due to an excessive risk of bleeding associated with this therapeutic regimen. This review summarizes randomized clinical trials and observational studies that compared triple therapy with a variety of different therapeutic options. Although the available evidence is not completely satisfactory and other studies are urgently needed, alternative regimens to triple therapy in AF patients undergoing PCI and stenting are promising, at least in terms of safety.



PlumX Metrics


Download data is not yet available.


How to Cite

Di Bari, Mauro, Alessandra Pratesi, Francesca M. Nigro, Irene Marozzi, and Stefano Fumagalli. 2018. “DAPT Plus Anticoagulant Therapy: The Difficult Coexistence Post-ACS in Older Patients With Atrial Fibrillation”. Monaldi Archives for Chest Disease 88 (2). https://doi.org/10.4081/monaldi.2018.957.